BioSpace News Archive

Sartorius Stedim Biotech, a leading partner of the biopharma industry, confirmed its preliminary figures for 2020 upon the release of its Universal Registration Document 2020 including the Annual Financial Report.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today an amendment of the agreement with Vyera Pharmaceuticals AG (“Vyera”) for the development of SLS-002 (intranasal racemic ketamine)

PureTech Health plc announced that Bharatt Chowrira, Ph.D., J.D., President and Chief of Business and Strategy, George Farmer, Ph.D., Chief Financial Officer, and Michael Chen, Ph.D., Head of Innovation, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26th at 10:00 AM EST.

AVEO Oncology announced that Michael Bailey, president and chief executive officer of AVEO, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:00 p.m. Eastern Time.

Rocket Pharmaceuticals, Inc., a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders announces participation at the following upcoming conferences

Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital Markets Day for investors, analysts and journalists

South Korea’s leading molecular diagnostics firm Seegene Inc. reported preliminary financial results for the fourth quarter and the fiscal year of 2020, showing records never seen before.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

Nordic Nanovector ASA announces its results for the fourth quarter and full year 2020. A live webcast presentation by Nordic Nanovector’s management team will take place at 08.30 CET.

Start of TET clinical program supports Ultimovacs’ goal of becoming a leader in cancer vaccine development